This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (19)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Dyshidrotic eczema is a common skin disease that probably accounts for about 5% to 20% of hand eczemas. Sometimes underlying trigger mechanisms can be detected, such as allergic contact dermatitis, dermatophytosis, bacterial foci, or drug eruptions, so that in these cases causal therapy can be applied. In the majority of cases, however, only symptomatic therapy can be offered, including the use of topical or systemic corticosteroids, phototherapy, and/or iontophoresis. Unfortunately, most of these attempts do not lead to long-term improvement and the majority of cases of dyshidrotic eczema relapse, persist for years, and still present a therapeutic problem. We describe a patient with dyshidrotic eczema that was resistant to conventional therapies but responded satisfactorily to the new immunosuppressive drug mycophenolate mofetil.

Report of a Case

A 39-year-old man experienced recurrent dyshidrotic eczema for 4 years. He had no history of allergic rhinitis, bronchial asthma, or other eczemas. The relapses were so severe that despite . . . [Full Text of this Article]

Comment

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Mycophenolate mofetil and skin diseases
Hartmann and Enk
Lupus 2005;14:s58-s63.
ABSTRACT  

Mycophenolate mofetil and skin diseases
Hartmann and Enk
Lupus 2005;14:s58-s63.
ABSTRACT  

Treatment of Linear IgA Bullous Dermatosis of Childhood With Mycophenolate Mofetil
Farley-Li and Mancini
Arch Dermatol 2003;139:1121-1124.
FULL TEXT  

Mycophenolate Mofetil-Induced Dyshidrotic Eczema
Semhoun-Ducloux et al.
ANN INTERN MED 2000;132:417-417.
FULL TEXT